PortalPublikationenCMV serostatus still has an important prognostic impact in d...

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT

Standard

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT. / Schmidt-Hieber, Martin; Labopin, Myriam; Beelen, Dietrich; Volin, Liisa; Ehninger, Gerhard; Finke, Jürgen; Socié, Gerard; Schwerdtfeger, Rainer; Kröger, Nicolaus; Ganser, Arnold; Niederwieser, Dietger; Polge, Emmanuelle; Blau, Igor W; Mohty, Mohamad.

in: BLOOD, Jahrgang 122, Nr. 19, 07.11.2013, S. 3359-64.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schmidt-Hieber, M, Labopin, M, Beelen, D, Volin, L, Ehninger, G, Finke, J, Socié, G, Schwerdtfeger, R, Kröger, N, Ganser, A, Niederwieser, D, Polge, E, Blau, IW & Mohty, M 2013, 'CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT', BLOOD, Jg. 122, Nr. 19, S. 3359-64. https://doi.org/10.1182/blood-2013-05-499830

APA

Schmidt-Hieber, M., Labopin, M., Beelen, D., Volin, L., Ehninger, G., Finke, J., Socié, G., Schwerdtfeger, R., Kröger, N., Ganser, A., Niederwieser, D., Polge, E., Blau, I. W., & Mohty, M. (2013). CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT. BLOOD, 122(19), 3359-64. https://doi.org/10.1182/blood-2013-05-499830

Vancouver

Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT. BLOOD. 2013 Nov 7;122(19):3359-64. https://doi.org/10.1182/blood-2013-05-499830

Bibtex

@article{0be04d73795d481f884a0e1d03aca9c5,
title = "CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT",
abstract = "We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16,628 de novo acute leukemia patients after allogeneic stem cell transplantation (allo-SCT). Compared with CMV-seronegative recipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival (44% vs 49%, P < .001) and overall survival (50% vs 56%, P < .001), and increased nonrelapse mortality (23% vs 20%, P < .001). Both groups showed a comparable relapse incidence and 2-year probability of graft-versus-host disease. The negative prognostic effects of CMV seropositivity of the donor and/or the recipient (vs CMV seronegativity of both) were significantly stronger for acute lymphoblastic leukemia (ALL) than for acute myeloid leukemia (AML), resulting in a markedly reduced 2-year overall survival (46% vs 55% for ALL compared with 52% vs 56% for AML). The important prognostic impact of donor/recipient CMV serostatus remained in a multivariate Cox regression analysis including the other prognostic variables. We conclude that donor and/or recipient CMV seropositivity is still associated with an adverse prognosis in de novo acute leukemia patients after allo-SCT despite the implementation of sophisticated strategies for prophylaxis, monitoring, and (preemptive) treatment of CMV.",
keywords = "Adolescent, Adult, Aged, Antibodies, Viral, Cytomegalovirus, Cytomegalovirus Infections, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Multivariate Analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Recurrence, Survival Analysis, Tissue Donors, Transplantation, Homologous",
author = "Martin Schmidt-Hieber and Myriam Labopin and Dietrich Beelen and Liisa Volin and Gerhard Ehninger and J{\"u}rgen Finke and Gerard Soci{\'e} and Rainer Schwerdtfeger and Nicolaus Kr{\"o}ger and Arnold Ganser and Dietger Niederwieser and Emmanuelle Polge and Blau, {Igor W} and Mohamad Mohty",
year = "2013",
month = nov,
day = "7",
doi = "10.1182/blood-2013-05-499830",
language = "English",
volume = "122",
pages = "3359--64",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

RIS

TY - JOUR

T1 - CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT

AU - Schmidt-Hieber, Martin

AU - Labopin, Myriam

AU - Beelen, Dietrich

AU - Volin, Liisa

AU - Ehninger, Gerhard

AU - Finke, Jürgen

AU - Socié, Gerard

AU - Schwerdtfeger, Rainer

AU - Kröger, Nicolaus

AU - Ganser, Arnold

AU - Niederwieser, Dietger

AU - Polge, Emmanuelle

AU - Blau, Igor W

AU - Mohty, Mohamad

PY - 2013/11/7

Y1 - 2013/11/7

N2 - We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16,628 de novo acute leukemia patients after allogeneic stem cell transplantation (allo-SCT). Compared with CMV-seronegative recipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival (44% vs 49%, P < .001) and overall survival (50% vs 56%, P < .001), and increased nonrelapse mortality (23% vs 20%, P < .001). Both groups showed a comparable relapse incidence and 2-year probability of graft-versus-host disease. The negative prognostic effects of CMV seropositivity of the donor and/or the recipient (vs CMV seronegativity of both) were significantly stronger for acute lymphoblastic leukemia (ALL) than for acute myeloid leukemia (AML), resulting in a markedly reduced 2-year overall survival (46% vs 55% for ALL compared with 52% vs 56% for AML). The important prognostic impact of donor/recipient CMV serostatus remained in a multivariate Cox regression analysis including the other prognostic variables. We conclude that donor and/or recipient CMV seropositivity is still associated with an adverse prognosis in de novo acute leukemia patients after allo-SCT despite the implementation of sophisticated strategies for prophylaxis, monitoring, and (preemptive) treatment of CMV.

AB - We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16,628 de novo acute leukemia patients after allogeneic stem cell transplantation (allo-SCT). Compared with CMV-seronegative recipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival (44% vs 49%, P < .001) and overall survival (50% vs 56%, P < .001), and increased nonrelapse mortality (23% vs 20%, P < .001). Both groups showed a comparable relapse incidence and 2-year probability of graft-versus-host disease. The negative prognostic effects of CMV seropositivity of the donor and/or the recipient (vs CMV seronegativity of both) were significantly stronger for acute lymphoblastic leukemia (ALL) than for acute myeloid leukemia (AML), resulting in a markedly reduced 2-year overall survival (46% vs 55% for ALL compared with 52% vs 56% for AML). The important prognostic impact of donor/recipient CMV serostatus remained in a multivariate Cox regression analysis including the other prognostic variables. We conclude that donor and/or recipient CMV seropositivity is still associated with an adverse prognosis in de novo acute leukemia patients after allo-SCT despite the implementation of sophisticated strategies for prophylaxis, monitoring, and (preemptive) treatment of CMV.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies, Viral

KW - Cytomegalovirus

KW - Cytomegalovirus Infections

KW - Female

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Prognosis

KW - Recurrence

KW - Survival Analysis

KW - Tissue Donors

KW - Transplantation, Homologous

U2 - 10.1182/blood-2013-05-499830

DO - 10.1182/blood-2013-05-499830

M3 - SCORING: Journal article

C2 - 24037724

VL - 122

SP - 3359

EP - 3364

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 19

ER -